Lepu Biopharma Co., Ltd. (HKG:2157)
Hong Kong · Delayed Price · Currency is HKD 4.235
+0.150 (3.67%)
Aug 20, 2026, 4:09 PM HKT
Lepu Biopharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 991.34 | 934.87 | 367.79 | 225.35 | 15.57 | - | |
Revenue Growth | 41.53% | 154.18% | 63.21% | 1347.16% | - | - |
Cost of Revenue | 109.23 | 89.59 | 74.82 | 28.28 | 2.01 | - |
Gross Profit | 882.12 | 845.28 | 292.97 | 197.08 | 13.57 | - |
Selling, General & Admin | 406.4 | 354.46 | 237.89 | 129.95 | 140.58 | 156.24 |
Research & Development | 406.73 | 400.71 | 437.7 | 458.07 | 524.29 | 791.21 |
Other Operating Expenses | 72.26 | 64.2 | 13.21 | -0.38 | -8.85 | -3.77 |
Operating Expenses | 885.38 | 819.37 | 688.81 | 587.65 | 656.02 | 943.68 |
Operating Income | -3.27 | 25.91 | -395.84 | -390.57 | -642.45 | -943.68 |
Interest Expense | -37.38 | -28.16 | -21.65 | -14.68 | -7.47 | -2.7 |
Interest & Investment Income | 5.39 | 5.39 | 4.67 | 8.18 | 8.35 | 9.1 |
Earnings From Equity Investments | -1.22 | -7.51 | -16.44 | -27.34 | -32.23 | -17.7 |
Currency Exchange Gain (Loss) | 7.05 | 7.05 | 1.33 | 0.21 | 37.75 | -2.41 |
Other Non Operating Income (Expenses) | -4.82 | -32.4 | 3.74 | 173.64 | -64 | -76.86 |
EBT Excluding Unusual Items | -34.24 | -29.72 | -424.19 | -250.56 | -700.05 | -1,034 |
Gain (Loss) on Sale of Investments | 289.44 | 289.44 | - | 220.26 | - | 5.37 |
Gain (Loss) on Sale of Assets | 0.91 | 0.91 | -0.01 | - | 0.61 | - |
Pretax Income | 256.11 | 260.64 | -424.19 | -30.3 | -699.44 | -1,029 |
Income Tax Expense | 1.68 | 1.75 | - | - | - | - |
Earnings From Continuing Operations | 254.43 | 258.89 | -424.19 | -30.3 | -699.44 | -1,029 |
Minority Interest in Earnings | -7.42 | 2.48 | 12.82 | 8.21 | 10.39 | 17.87 |
Net Income | 247.01 | 261.36 | -411.38 | -22.1 | -689.05 | -1,011 |
Net Income to Common | 247.01 | 261.36 | -411.38 | -22.1 | -689.05 | -1,011 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,396 | 1,755 | 1,690 | 1,659 | 1,641 | 1,520 |
Shares Outstanding (Diluted) | 1,396 | 1,755 | 1,690 | 1,659 | 1,641 | 1,520 |
Shares Change | -18.38% | 3.82% | 1.87% | 1.14% | 7.92% | 33.97% |
EPS (Basic) | 0.18 | 0.15 | -0.24 | -0.01 | -0.42 | -0.66 |
EPS (Diluted) | 0.18 | 0.15 | -0.24 | -0.01 | -0.42 | -0.66 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -57.64 | -229.31 | -278.84 | -591.38 | -835.12 |
Free Cash Flow Per Share | - | -0.03 | -0.14 | -0.17 | -0.36 | -0.55 |
Gross Margin | 88.98% | 90.42% | 79.66% | 87.45% | 87.12% | - |
Operating Margin | -0.33% | 2.77% | -107.62% | -173.32% | -4125.67% | - |
Profit Margin | 24.92% | 27.96% | -111.85% | -9.80% | -4424.94% | - |
Free Cash Flow Margin | - | -6.17% | -62.35% | -123.73% | -3797.71% | - |
EBITDA | 71.13 | 105.38 | -313.67 | -306.66 | -564.63 | -866.49 |
EBITDA Margin | 7.18% | 11.27% | -85.28% | -136.08% | - | - |
D&A For EBITDA | 74.4 | 79.46 | 82.16 | 83.91 | 77.82 | 77.18 |
EBIT | -3.27 | 25.91 | -395.84 | -390.57 | -642.45 | -943.68 |
EBIT Margin | -0.33% | 2.77% | -107.62% | -173.31% | - | - |
Effective Tax Rate | 0.66% | 0.67% | - | - | - | - |